Shanghai Fosun Pharmaceutical To Enter China's Injectable Market
This article was originally published in PharmAsia News
Shanghai Fosun Pharmaceutical recently revealed that its two wholly-owned subsidiaries, Fosun International and Fosun Industrial, signed an agreement to buy from Beijing Hexin Boye Consultancy and Aleph Biomedical the totaling stake of 75 percent in Aleph Biomedical, allegedly at RMB 660 and 9 million
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.